Benzinga | Aug 23, 2021 01:52PM EDT

DSS Subsidiary Impact Biomedical Reports Positive Test Results For 3FDB DEET Booster Technology

* Document Security Systems, Inc. (NYSE:DSS), subsidiary Impact Biomedical, Inc, along with its scientific research partner Global Research and Discovery Group Sciences, GRDG, announced encouraging results from clinical tests of its 3FDB (DEET Booster) technology.

* The results suggest that 3FDB can boost the effectiveness of mosquito repellants, specifically DEET. Working with an independent lab, GRDG conducted three tests involving the mosquito (Aedes aegypti).

* Daryl Thompson, Director of Scientific Initiatives at GRDG, stated, "These tests represent an important development in addressing mosquito-borne diseases and could signal a new frontier of protection strategies."

* Recently, Impact Biomedical and GRDG received a U.S. Patent for 3FDB (US 10,966,424), a Functional Fragrance Formulation, which increases the current mosquito repellants' effectiveness through light and a fragrant compound derived from botanical oils.

* Price Action: DSS shares are trading lower by 3.16% at $1.2686 on the last check Monday.